Self-adjuvanting therapeutic peptide-based vaccine induce CD8+ cytotoxic T lymphocyte responses in a murine human papillomavirus tumor model by Liu, Tzu-Yu et al.
Send Orders for Reprints to reprints@benthamscience.net 
 Current Drug Delivery, 2015, 12, 000-000 1 
 1567-2018/15 $58.00+.00 © 2015 Bentham Science Publishers 
Self-Adjuvanting Therapeutic Peptide-Based Vaccine Induce CD8+ Cyto-
toxic T Lymphocyte Responses in a Murine Human Papillomavirus Tumor 
Model 
Tzu-Yu Liu1, Ashwini Kumar Giddam1, Waleed M. Hussein1, Zhongfan Jia2, Nigel A.J. McMillan3, 
Michael J. Monteiro2, Istvan Toth1,4 and Mariusz Skwarczynski1,* 
1School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane QLD 4072, Australia; 
2Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane QLD 4072,  
Australia; 3Cancer Research Centre, Griffith Health Institute and School of Medical Science, Griffith University,  
Gold Coast, QLD 4222, Australia; 4School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, 
Australia 
Abstract: Vaccine candidates for the treatment of human papillomavirus (HPV)-associated cancers are aimed to activate 
T-cells and induce development of cytotoxic anti-tumor specific responses. Peptide epitopes derived from HPV-16 E7 on-
cogenic protein have been identified as promising antigens for vaccine development. However, peptide-based antigens 
alone elicit poor cytotoxic T lymphocyte (CTL) responses and need to be formulated with an adjuvant (immunostimulant) 
to achieve the desired immune responses. We have reported the ability of polyacrylate 4-arm star-polymer (S4) conju-
gated with HPV-16 E744-57 (8Qmin) epitope to reduce and eradicate TC-1 tumor in the mouse model. Herein, we have stud-
ied the mechanism of induction of immune responses by this polymer-peptide conjugate and found prompt uptake of con-
jugate by antigen presenting cells, stimulating stronger CD8+ rather than CD4+ or NK cell responses  
Keywords: peptide subunit vaccine, human papillomavirus, therapeutic anticancer vaccine, star-polymer, polyacrylate, self-
adjuvanting, cytotoxic T lymphocyte (CTL) responses. 
INTRODUCTION 
 Human papillomavirus (HPV) is major cause of all cervi-
cal cancers with HPV type 16 (HPV-16) infection causing 
the majority of HPV-related cancers [1]. While prophylactic 
HPV vaccines have already been developed and commercial-
ized, they only protect the host against viral infection but 
have no therapeutic properties to eradicate established HPV 
infection. Thus, there is strong demand for development of 
therapeutic vaccines to eradicate HPV and control cervical 
cancer mortality. Such vaccines can provide a safe alterna-
tive to classical chemotherapy as they use the natural im-
mune system of our body to create a potent immune response 
against tumor cells. 
 Therapeutic HPV vaccine candidates are aimed to elicit 
cytotoxic T-cell responses and mainly focus on targeting 
HPV E7 oncogenic protein, as E7 protein is required for tu-
morigenesis and maintenance of tumor growth [1]. The 
whole oncoprotein cannot be used in vaccine formulation as 
it can induce genomic instability in normal human cells. 
However, peptide-based vaccines use only minimal non-
oncogenic epitopes necessary to stimulate immune re-
sponses. In general, peptides alone are non-immunogenic 
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and the addition of an external adjuvant (immunostimulant) 
to induce the desired immune responses was required in all 
reported therapeutic peptide-based HPV vaccine approaches 
[1]. To date, only a limited number of adjuvants have been 
approved for human use and they are often toxic or their 
efficacy is low [2]. Thus, the development of new adjuvants 
or self-adjuvanting delivery systems with potent immuno-
modulatory properties and without adverse toxicity is of ma-
jor importance in the field of anti-cancer therapy [3, 4]. A 
large number of experimental adjuvants and self-adjuvanting 
systems are reported to induce humoral immune responses; 
however, triggering of cellular immunity against cancer cells 
is a particular challenge [5]. 
 Previously, we have demonstrated that the polyacrylate 
dendrimers conjugated to multiple copies of minimal B-cell 
epitope was able to induce humoral immunity without the 
use of an additional immunostimulant [6-8]. We also re-
ported that star polyacrylate-based vaccine delivery platform 
had the ability to reduce and eradicate tumor cells that pro-
duce the E7 oncoprotein in the mouse model. The lead vac-
cine candidate called S4-8Qmin possessing 8Qmin (E744-57, 
QAEPDRAHYNIVTF) epitope was able to shrink and eradi-
cate E7-expressing TC-1 tumors after a single-dose immuni-
zation in mice [9]. It has been proven that polymer-peptide 
conjugates can induce humoral immunity but the mode of the 
anti-cancer action of self-adjuvanting polymer-peptide con-
jugates has not been studied yet [10]. In this work, we have 
studied the mechanism of induction of immune responses by 
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these polymer-peptide conjugates. It was found that the con-
jugates were promptly taken up by antigen presenting cells 
including macrophages and dendritic cells (DCs). In addi-
tion, we had proven that CD8+ cytotoxic T lymphocytes 
(CTLs) played a major role in anti-tumor immunity upon 
administration of polymer-peptide conjugates.  
MATERIALS AND METHODS 
Synthesis of Vaccine Candidate P(tBA37-≡)4-8Qmin  
(S4-8Qmin) 
 Synthesis of polymer-peptide conjugates S4-8Qmin 
(Scheme 1) has been described in detail previously [9]. 
Briefly, the alkyne-functionalized poly(t-butyl) acrylate 
(P(tBA) 4-arm star-polymer (S4) was produced with the help 
of atom-transfer radical polymerization (ATRP) [11]. The 
8Qmin epitope ended with azide (N3CH2CO-QAEPDRAHY-
NIVTFCCKCD-NH2) was synthesized using Fmoc-SPPS 
and conjugated to the polyacrylate S4 via 1,3-dipolar copper-
catalyzed alkyne–azide cycloaddition (CuAAC) “click” reac-
tion [12] to produce S4-8Qmin. Then, the resulting S4-8Qmin 
conjugate formed particles via self-assembled process in a 
DMF/water mixture. The dialysis against endotoxin-free 
water (Millipore, Queensland, Australia) was performed to 
remove the excess of peptide, residual copper and DMF. 
Particle Size Measurement  
 The particle size and size distribution (span) of the con-
jugate was measured using the laser diffraction method 
(Mastersizer 2000, Malvern Instruments, UK) after formulat-
ing the conjugate in PBS. The geometrical diameter was pre-
sented as volume median diameter (D50%). The size distri-
bution (span) value of the formulation was defined by a 
standard formula: 
Span = (D90%-D10%)/D50% 
 D10%, D50% and D90% are the particle diameters for 
10th, 50th and 90th percentile of the undersized particle distri-
bution curve [13]. The size of particle of the conjugate was 
12 µm and size distribution was narrow (span < 1.2).  
Uptake of Conjugates by Dendritic Cells and Macro-
phages 
 An antigen presenting cells uptake assay was performed 
in a similar manner as described previously [14, 15]. Uptake 
of S4-8Qmin by DCs and macrophages was investigated using 
splenocytes marked with CD11c-A660 (eBioscience) and 
F4/80-APC-Cy7 (BioLegend, Pacific Heights Blvd, San Di-
ego, CA, USA) antibodies for DCs and macrophages, respec-
tively. Spleen was passed through stainless steel mesh to 
produce single-cell suspensions. Erythrocytes were lysed by 
erylysis buffer (Sigma-Aldrich) and the remaining cell popu-
lation was placed in a 6-well plate at a density of 2 x 105 
cells/well in phenol free IMDM Glutamax medium (Gibco®, 
Life Technologies), supplemented with 10% FBS, 50 µM 2-
mercaptoethanol (Gibco®, Life Technologies), 100 U/ml 
penicillin, and 100 µg/ml streptomycin (Gibco®, Life Tech-
nologies). The S4-8Qmin was labeled with Dil (1,1’ dioctade-
cyl-3,3,3’,3’tetramethylindocarbocyanine perchlorate) (Vy-
brant®, Life Technologies) by adding 0.5 µl of Dil to 100 µl 
of S4-8Qmin in PBS and incubating for 30 min (Dil rapidly 
adsorbs to the S4-8Qmin). Dil-labeled S4-8Qmin or Dextran-
FITC (positive control) were added to the wells and incu-
bated overnight. The adherent cells were scraped from the 
plate and incubated with Fc-block for 30 min at 4oC, centri-
fuged and re-suspended in buffer containing CD11c-A660 
and F4/80-APC-Cy7 antibodies for 30 min at 4°C. The cells 
were then centrifuged and re-suspended in 0.5 mL of FACS 
buffer (PBS, 0.02% sodium azide, 0.5% BSA) and analyzed 
using an LSR II flow cytometer (BD Biosciences). The fluo-
rescence intensities of DCs and macrophages treated with 
PBS were also measured as controls. The actual uptake was 
calculated as the percentage of cells double positive for  
S4-8Qmin (Dil) and CD11c (A660), or S4-8Qmin (Dil) and 
F4/80 (APC-Cy7) markers. 
Mice  
 C57BL/6 (female, 6-8 weeks old) mice were purchased 
from Animal Resources Centre (Perth, Western Australia). 
All animal studies were approved by The University of 
Queensland Animal Ethics Committee (DI/034/11/NHMRC) 
and performed according to Australia National Health and 
Medical Research Council (NHMRC) guidelines. 
Tumor Cells 
 TC-1 cells, a mouse C57BL/6 lung epithelial cell line 
transformed with ras oncogenes, HPV-16 E6 and E7, were 
kindly provided by TC Wu [16]. TC-1 cells were cultured in 
RPMI 1640 medium (Gibco) supplemented with 10% heat 
inactivated fetal bovine serum (Gibco) and 1% nonessential 
amino acids (Sigma-Aldrich) at 37 °C/5% CO2. For injection 
into mice, TC-1 cells were washed with 1× DPBS, trypsinized, 
resuspended and viable cells counted (trypan blue exclu-
sion). 
Immunizations 
 Prior to immunization, groups of C57BL/6 mice (5 per 
group) were injected subcutaneously with 2×105 TC-1 tumor 
cells/mouse suspended in 100 µL 1× DPBS in the right flank 
(day 0), and rested for 3 days to allow for tumor formation. 
On day 3 after tumor implantation, mice subsequently re-
ceived a single subcutaneous immunization (100 µL total 
volume/mouse) at the tail base. This consisted of 100 µg of 
S4-8Qmin (equivalent of 30 µg of 8Qmin epitope) in a total 
volume of 100 µL 1× DPBS (in 6 groups) or 1× DPBS (un-
treated control group). The size of the tumors was measured 
every two days using calipers (and palpation) for each 
mouse. The tumor volume was calculated using the formula 
[17]: 
Tumor volume (cm3) = π × [largest diameter × (perpendicu-
lar diameter)2]/6 
 The mice were euthanized when tumors volume was 
greater than 1 cm3 or tumor bleeding was observed. 
In vivo Antibody Depletion Experiments 
 In vivo antibody depletions have been described previ-
ously [18]. The antibody depletions were started prior to 
immunization. Groups of mice (5 groups vaccinated with  
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S4-8Qmin, 5 mice per group) were injected intraperitoneally 
(i.p.) with either 0.5 mg of anti-CD4+ (clone GK 1.5, BioX-
cell) [19], 0.5 mg of anti-CD8+ (clone 53-6.72, BioXcell) 
[19], 0.5 mg of anti-NK (PK136, BioXcell) [16] or 0.5 mg of 
control antibody (rat-IgG and mouse-IgG, BioXcell). Each 
antibody (100 µL) was administered i.p. on day −1, 0, 1 and 
once per week throughout the experiment. This antibody 
treatment resulted in greater than 99% depletion of CD4+ and 
CD8+ T-cells, and 92% depletion of NK cells as assessed by 
flow cytometry. Depleted mice were subsequently chal-
lenged with TC-1 tumor on day 0 and immunized with vac-
cine S4-8Qmin or PBS on day 3. 
Statistical Analysis 
 GraphPad Prism 6 software was used for data analysis. 
Results of tumor volumes among all treatments were evalu-
ated by ANOVA test. Kaplan-Meier survival curves was 
used for the analysis of tumor challenge experiments. Statis-
tical significance was considered when p< 0.05.  
RESULTS AND DISCUSSION 
 We designed and synthesized polymer-peptide chimeras 
consisting of a polyacrylate core and multiple copies  
of 8Qmin (QAEPDRAHYNIVTF; E744-57). The conjugate, 
S4-8Qmin, was synthesized by copper-catalyzed alkyne–azide 
1,3-dipolar cycloaddition (CuAAC) “click” reaction of 
polymer S4 with the peptide epitope 8Qmin in the presence of 
copper wires (Scheme 1), then self-assembled into particles. 
Elemental analysis was used to confirm formation of the 
product [7] as the conjugate contained higher nitrogen/ car-
bon ratio (N/C = 0.085) in comparison to that of S4  
(N/C = 0.004). The exact substitution of polymer core with 
the peptide epitopes was calculated based on the comparison 
of theoretical and observed N/C ratios. The efficacy of con-
jugation was high (88% substitution). The S4-8Qmin was self-
assembled into microparticles with an average diameter of 
12 µm and narrow size distribution (span < 1.2). The  
S4-8Qmin was built with a hydrophobic polymer core and a 
hydrophilic peptide epitope. It was demonstrated that the 
balance between hydrophilic and hydrophobic properties of 
individual segments of such amphiphiles was responsible for 
the size of formed particles and the less polar peptide epi-
topes attached to the polymer core produced larger particles 
[20]. The production process was highly reproducible in 
terms of both substitution ratio and size. 
 The HPV-16 E7 protein epitope 8Qmin (QAEPDRA-
HYNIVTF; E744-57) contained a CTL epitope (CD8+ CTL) 
and a T-helper cell (CD4+) epitope (Fig. 1) [21]. This com-
bination made 8Qmin a promising candidate to stimulate im-
mune responses against tumor cells. As peptides themselves 
are very poor immunogens, an additional adjuvant and/or 
delivery system is essential to induce strong immune re-
sponses. Dendrimers are synthetic polymers with well-
defined structure which may have similar properties to that 
of biomolecules and antigens [22]. The antigens can be 
conjugated to the periphery of dednrimer “arms” to creat 
multifunctional bio-macromolecule. We have selected poly-
acrylate as the most promising candidate for vaccine delivery 
as polyacrylic acid and its esters are easy to synthesize, have 
very limited toxicity and were reported to possess adjuvant-
ing properties when mixed with an inactivated virus [23, 24]. 
Here, the 8Qmin epitope was applied as an antigen, while S4 
acted as a delivery platform. We have reported previously 
that polyacrylate polymer conjugated to peptide epitopes 
were capable to shrink and eradicate TC-1 tumor expressing 
E7 protein in the mouse model [9]. However, biological 
evaluation has not yet been performed to demonstrate immu-
nological properties of this construct. 
 
 
Scheme (1). Synthesis of polymer-peptide conjugates S4-8Qmin. 
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 Antigen presenting cells (APCs) play a crucial role in 
triggering an immune response. They continuously sample 
and process the antigens and present them to CD8+and CD4+ 
T-cells via MHC-I and MHC-II molecules, respectively [25]. 
Antigens in particle form are expected to be efficiently taken 
up by APCs [26]. It has also been demonstrated that only the 
particles, which were efficiently taken up by DCs, induced a 
strong antigen-specific CD8+ T-cell response [27]. Thus, in 
the present study, we investigated the in vitro uptake of con-
jugate S4-8Qmin by DCs and macrophages by incubating 
labeled S4-8Qmin with DCs and macrophages derived from 
splenocytes. The resulting cell-associated fluorescence (Dil 
labeled S4-8Qmin and CD11c-A660 or F4/8- APC-Cy7) was 
measured by flow cytometry. Approximately 25% of DCs 
and 15% of macrophages showed uptake of S4-8Qmin (Fig. 2). 
Interestingly, despite their relatively large size the particles 
were more efficiently taken up by DCs than macrophages 
(although the opposite trend was expected [28]); however, 
this difference was not statistically significant. 
 
 
 
Fig. (2). Uptake of S4-8Qmin by mice splenocyte-derived DCs and 
macrophages. The experiments were performed in triplicate, and 
data are presented as a percentage of cells double positive for  
S4-8Qmin (Dil) and CD11c (A660) or F4/80 (APC-Cy7). CD11c 
(A660) or F4/80 (APC-Cy7) were markers characteristic of DCs 
and macrophages, respectively. Bars represent the mean ± S.D. of 
three experiments. 
 
 To determine the ability of the vaccine candidate (with-
out the presence of any adjuvant) to induce a lymphocytic 
response, in vivo antibody depletion experiments were per-
formed [18]. Five groups of mice were injected with anti-
CD4+, anti-CD8+, anti-NK, control rat-IgG and control 
mouse-IgG antibodies. Then, tumor cells were injected, and 
the vaccine candidate was administrated in a single dose 3 
days later. Treatments with PBS and S4-8Qmin without de-
pleting antibodies served as the untreated and treated con-
trols, respectively. All mice immunized with PBS, S4-8Qmin/ 
anti-CD8+ and S4-8Qmin/anti-CD4+ were sacrificed due to 
tumor burden by day 29, 27 and 29, respectively (Fig. 3a).  
In contrast, the survival rate of the mice immunized with  
S4-8Qmin, S4-8Qmin/rat-IgG, S4-8Qmin/mouse-IgG and  
S4-8Qmin/anti-NK was 40%, 40%, 60% and 20%, respec-
tively. Among the mice groups treated with S4-8Qmin, the 
survival rate was statistically significantly lower only in the 
CD8+-depleted group when compared with mice treated with 
S4-8Qmin only (p<0.01) (Fig. 3a). Tumor-bearing mice 
treated with S4-8Qmin, S4-8Qmin/rat-IgG, S4-8Qmin/mouse-
IgG, S4-8Qmin/anti-CD4+ and S4-8Qmin/anti-NK showed 
slower tumor growth than those treated with S4-8Qmin/anti-
CD8+ (p<0.05) and PBS (Fig. 3b). Mice treated with the con-
jugate but depleted of CD8+ T-cells showed fast tumor 
growth in a manner similar to the untreated control group 
(PBS). These data suggested that S4-8Qmin anti-tumor po-
tency was related to tumor-associated antigen-specific CD8+ 
T-cell responses. Administration of the conjugate might also 
result in stimulation of CD4+ T-cells as all mice in the group 
injected with anti-CD4+ antibodies were moribund within 30 
days (however, the difference in survival rate was not sig-
nificant when compared to the positive control). In previous 
studies on peptide-based HPV vaccine candidates, which 
targeted the E7 oncogene, similar T-cell responses were re-
ported but the use of external adjuvant was essential [29, 30].  
 In this work, we have clearly demonstrated that the 
polymer-peptide conjugate could serve as a self-adjuvanting 
delivery system and the conjugate was promptly taken up by 
APCs and stimulated CD8+ T-cells to produce a therapeutic 
effect against tumor cells. The self-adjuvanting properties of 
the conjugates can be related to their ability to form particles. 
[28, 31]. It has been demonstrated that antigens in particle 
form are expected to be more efficiently taken up by APCs 
[26]. In addition, large particles are able to induce strong 
immune responses through the depot effect (i.e., retention 
and slow release of an antigen at the injection site) [32]. 
Along the same line, activation of cellular immunity is often 
enhanced by depot-forming adjuvants, which elongate time 
of antigen presentation to the immune cells [31]. Thus, it 
might be assumed that microparticles, presented here, have 
formed a depot and have the ability to induce cellular immu-
nity following uptake by peripheral APCs. Though, the in-
duction of immunity as a consequence of disaggregation of 
these self-assembled particles and slow release of the conju-
gate in the form of single molecules or smaller particles can-
not be ruled out. 
CONCLUSION 
 In conclusion, we synthesized and evaluated a delivery 
system for anti-cancer peptide-based vaccines. This delivery 
system, based on a polyacrylate polymer conjugated with 
HPV-16 E7 protein-derived peptide epitope, induced potent 
therapeutic immune responses against a tumor without the 
use of additional adjuvant. Until now, the ability of self-
assembled polymer-peptide conjugates to induce CD8+ CTL 
immunity has not been proven. In this work, we have shown 
that the polymer-peptide conjugate S4-8Qmin was efficiently 
taken up by APCs, that is, DCs and macrophages, and CD8+ 
CTLs have played a major role in the anti-tumor immunity 
induced by S4-8Qmin. Thus, we have developed the first self-
adjuvanting therapeutic peptide vaccine delivery system 
against cervical cancer. We believe that this strategy can be 
  
Fig. (1). The sequence of the 8Qmin and incorporated CTL (CD8+) 
and the T-helper cell (CD4+) epitopes. 
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used to design other therapeutics that will be able to trigger 
CTL responses against targeted diseases. 
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